Lifetime risks of second primary malignancies after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma
Open Access
- 27 January 2024
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (2) , 1-10
Abstract
Objectives: Survivors after pediatric Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are with lifetime risk for second primary malignancy (SPM). This necessitates a thorough analysis to better understand the potential long-term health implications for these individuals. Methods: We used a US-wide population-based cancer registry data to quantify the SPM risk and identify its incidence patterns among pediatric lymphoma patients. Results: We observed 4.74-fold (95% CI 4.27–5.25) and 3.40-fold (95% CI 2.78–4.10) increased risks of SPM in survivors after pediatric HL and NHL, respectively. Through over 40 years’ follow-up, the cumulative incidence of SPM for pediatric lymphoma was persistently increasing, and here we firstly report the high 40-year cumulative incidence rates of SPM, 22.2% for HL and 12.6% for NHL, suggesting that SPM accounts for a great proportion of deaths among survivors. Of 6805 pediatric lymphomas, 462 (6.36%) developed a SPM, especially second breast and thyroid cancer, followed by hematologic neoplasms including leukemia and NHL. The competing risk analysis demonstrated gender, lymphoma subtype and radiotherapy were significantly associated with SPM. Different risk patterns of SPM were identified between pediatric HL and NHL. Chemotherapy accelerated SPM development but did not increase its incidence risk. Conclusion: Overall, patients after pediatric lymphoma can be with high lifetime risk of SPM, and more attention should be paid to SPM-related signs for early detection and intervention.Keywords
Funding Information
- the 2024 College Students’ Innovative Entrepreneurial Training Plan Program (Project No. C2024130171, Project No. C2024130171)
- National Natural Science Foundation of China (No. 82303773, No. 82303772, No. 82204490, No. 82303694, No. 82303773, No. 82303772, No. 82204490, No. 82303694)
- Natural Science Foundation of Sichuan Province (No. 2023NSFSC1885, No. 2023NSFSC1885)
- Key Research and Development Program of Sichuan Province (No. 2023YFS0306, No. 2023YFS0306)
This publication has 13 references indexed in Scilit:
- Second primary cancers in non‐Hodgkin lymphoma: Family history and survivalInternational Journal of Cancer, 2019
- Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family HistoryJournal of Clinical Oncology, 2017
- Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based studyJournal of Cancer Research and Clinical Oncology, 2015
- Second primary head and neck cancer after Hodgkin lymphoma: A population‐based study of 44,879 survivors of Hodgkin lymphomaCancer, 2015
- Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma SubtypeJournal of Clinical Oncology, 2010
- Subsequent Neoplasms in 5-Year Survivors of Childhood Cancer: The Childhood Cancer Survivor StudyJNCI: Journal of the National Cancer Institute, 2010
- Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor StudyBlood, 2008
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Skin cancer and non-Hodgkin's lymphoma as second malignanciesEuropean Journal of Cancer, 2003
- Second malignancy after treatment of childhood non-Hodgkin lymphomaCancer, 2001